CFTR Modulators for the Treatment of Cystic Fibrosis
- P T. 2014 Jul;39(7):500-11.
Defects in a single gene lead to the defective proteins that cause Cystic Fibrosis, making the disease an ideal candidate for mutation-targeted therapy. Although ivacaftor is currently the only FDA-approved CFTR modifier, Others are in development.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
-
-